Abstract:Introduction: Five biologic medications have been proven to be efficacious to treat Ulcerative Colitis (UC), three tumor necrosis factor inhibitors (infliximab, adalimumab, and golimumab) and two Selective Adhesion Molecule (SAM) inhibitors (vedolizumab and etrolizumab). The vast majority of evidence supporting their individual efficacy is based on randomized controlled trials (RCTs) with placebo as the comparator arm. We performed a network metaanalysis (NMA) to determine the comparative efficacy of these biologic medications for the induction of clinical response in the treatment of ulcerative colitis Methods: Studies were extracted from an electronic literature search of PubMed, MEDLINE and EMBASE of all relevant RCTs. 9 RCTs, including 3,265 patients, were identified. The main outcome of interest for efficacy: induction of response, defined as a decrease from baseline in the total Mayo score by at least 3 points and a relative decrease by at least 30% with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1. There were several outcomes of interest for safety, primarily serious infections, serious adverse events and adverse events causing discontinuation of the drug. For each outcome, a fixed-effects meta-analysis was employed to compare each drug to placebo. A mixed-treatment comparisons analysis was then used to compare each of these drugs to one another indirectly. Calculation of the probability that each treatment is best was implemented using the Bayesian Markov chain Monte Carlo method. Results: Patients taking Adalimumab had a 67% reduced likelihood of inducing response compared to Infliximab (RR 0.43 95% CI 0.27-0.72). In terms of rank probability, Infliximab had the highest probability of inducing response compared to Adalimumab and Vedolizumab. Overall, TNF inhibitors had a higher rank probability of inducing response compared to SAM inhibitors. In terms of adverse events, SAM inhibitors had a higher rank probability of causing adverse events when compared to TNF inhibitors. The degree of incoherence was low for all outcomes. Conclusion: This NMA to date is the first to compare the two groups of biologics, TNF inhibitors and SAM inhibitors including the new SAM inhibitoretrolizumab in the induction of response with different efficacy outcomes. The results of the study showed that TNF inhibitors seem to be more efficacious in inducing response in ulcerative colitis when compared to SAM inhibitors.

Effect of single‐dose injection of vitamin D on immune cytokines in ulcerative colitis patients: a randomized placebo‐controlled trial

Administration of Vitamin D3 Improves Hemoglobin Level by Regulating TNF-a and IL-6 in DSS-induced Colitis Mice

Vitamin D Attenuates Ulcerative Colitis by Inhibiting ACSL4-Mediated Ferroptosis

[Effects of oral vitamin D3 supplementation in Crohn's disease patients: Modulation of clinical active/remission phases by pro-inflammatory cytokines profile and oxidative stress]

Corticosteroid Therapy in Ulcerative Colitis: Clinical Response and Predictors.

Ameliorating Effects of Vitamin K2 on Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice

Correlations of Inflammatory Cytokines in the Intestinal Mucosa, Serum Inflammation, Oxidative Stresses and Immune Changes with Vitamin Deficiency in Ulcerative Colitis Patients

Effectiveness of a novel diet in attenuation of clinical activity of disease in patients with ulcerative colitis: a randomized, clinical trial

Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 - A Randomized Clinical Trial

Sa1796 Diet-Induced Secretion of Incretins is Regulated by Nutrients in the Stomach

Inhibition of Histone Deacetylation by MS-275 Alleviates Colitis by Activating the Vitamin D Receptor.

High-dose vitamin D3 supplementation decreases the number of colonic CD103+ dendritic cells in healthy subjects

Impact of Serum 25OHD Level on Disease Activity and Quality of Life in Patients with Ulcerative Colitis

The Correlation Between Serum 25-Hydroxyvitamin D Level and Ulcerative Colitis: a Systematic Review and Meta-Analysis.

High Dose Vitamin D supplementation alters faecal microbiome and predisposes mice to more severe colitis

Effect of vitamin D supplementation on clinical outcome and biochemical profile in South Indian population with vitamin D-deficient chronic urticarial - A randomized double-blind placebo controlled trial

Effects of Spirulina supplementation in patients with ulcerative colitis: a double-blind, placebo-controlled randomized trial

Vitamin D improves inflammatory bowel disease outcomes: Basic science and clinical review

P436 Evaluation of targeted vitamin D supplementation regimen in postoperative patients with Crohn’s disease

Intestinal vitamin D receptor knockout protects from oxazolone-induced colitis

Bolus injection of newly synthesized vitamin E derivative ETS-GS for the treatment of acute severe ulcerative colitis in a mouse model. New vitamin E derivative for acute severe UC